Login to Your Account

Regulatory NEWS

Since participant data will form the bedrock of the Precision Medicine Initiative (PMI), those who gather, store and use that information will have to give more than lip service to protecting it and using it responsibly.

HONG KONG – As part of its efforts to continue reforming China's medical system, the National Health and Family Planning Commission (NHFPC) slashed the price of three top-selling drugs of both foreign and domestic companies by more than half.

As an FDA advisory committee prepares for a double header this week on two fixed-combination diabetes drugs, the agency seems to be balking a bit at the match-up of a basal insulin product that, when used alone, has a wide effective dose range with a GLP-1 receptor agonist that has only one or two recommended effective doses.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: